Arintra vs Moderna

Side-by-side comparison of AI visibility scores, market position, and capabilities

Moderna leads in AI visibility (90 vs 36)
Arintra logo

Arintra

EmergingDigital Health

AI Medical Coding

Raised $21M Series A (Aug 2025) led by Peak XV Partners with Endeavor Health Ventures and YC. Coding Copilot enables 90% faster chart coding. 5%+ revenue uplift, 43%+ fewer denials.

AI VisibilityBeta
Overall Score
D36
Category Rank
#524 of 596
AI Consensus
78%
Trend
stable
Per Platform
ChatGPT
40
Perplexity
38
Gemini
41

About

Arintra is an AI medical coding platform that autonomously codes clinical charts with no human intervention, delivering measurable improvements in coding accuracy and speed. The company raised $21 million in Series A financing in August 2025 led by Peak XV Partners (formerly Sequoia India/SEA), with Endeavor Health Ventures and Y Combinator as co-investors. The Coding Copilot enables medical coders to work 90% faster by surfacing recommended codes with supporting clinical documentation.

Full profile
Moderna logo

Moderna

LeaderHealthcare Tech

Enterprise

mRNA pioneer with $3.2B FY2024 revenue (down from $18.4B 2022 COVID peak); mRESVIA RSV vaccine approved 2024; personalized cancer vaccine with Merck shows 44% recurrence reduction in melanoma.

AI VisibilityBeta
Overall Score
A90
Category Rank
#2 of 596
AI Consensus
83%
Trend
stable
Per Platform
ChatGPT
92
Perplexity
93
Gemini
89

About

Moderna is a clinical-stage biotechnology company that pioneered the development of messenger RNA (mRNA) therapeutics and vaccines, founded in 2010 by Noubar Afeyan, Robert Langer, Kenneth Chien, Stéphane Bancel, and others in Cambridge, Massachusetts, where it is headquartered and trades on Nasdaq (MRNA). The company achieved extraordinary commercial success with Spikevax, its COVID-19 mRNA vaccine developed in partnership with the U.S. government in 2020—generating $18.4 billion in COVID vaccine revenues in 2022 at peak—before experiencing a severe revenue decline as global COVID booster demand normalized. For FY2024, Moderna generated approximately $3.2 billion in revenues, with Spikevax and the reformulated XBB.1.5-targeting COVID vaccine contributing the majority, while the company's significant R&D investment pipeline consumed most operating cash flows.

Full profile

AI Visibility Head-to-Head

36
Overall Score
90
#524
Category Rank
#2
78
AI Consensus
83
stable
Trend
stable
40
ChatGPT
92
38
Perplexity
93
41
Gemini
89
33
Claude
96
34
Grok
95

Key Details

Category
AI Medical Coding
Enterprise
Tier
Emerging
Leader
Entity Type
brand
company

Capabilities & Ecosystem

Capabilities

Only Arintra
AI Medical Coding

Integrations

Only Moderna
Moderna is classified as company.

Track AI Visibility in Real Time

Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.